Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II bi-weekly docetaxel, carboplatin, cetuximab for unresectable head and neck cancer
jRCTs051220137Phase 2Recruiting
- Start
- Jan 2023
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel, carboplatin and cetuximab in head and neck squamous cell carcinoma (HNSCC). Primary endpoints: Dose-limiting toxicities (DLTs) during phase I and Objective response rate of bi-weekly docetaxel, carboplatin, cetuximab (bwDCE) in phase II. Started Jan 2023; status: recruiting.
02
Drugs
docetaxelcarboplatincetuximab
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on jRCTs051220137.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051220137.